Please login to the form below

Not currently logged in
Email:
Password:

Lyxumia

This page shows the latest Lyxumia news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua. European Commission licenses the once-daily version of Lantus and Lyxumia. ... The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide)

Latest news

More from news
Approximately 13 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted ... With a single daily injection and only one step to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics